A positive response was demonstrated in carriers of HER2 mutations treated with neratinib and, if ER-positive, with fulvestrant, as well as in carriers of AKT1 mutations and ER-positive BC treated with capivasertib plus fulvestrant. This evidence concerns the gene ERBB2 and breast cancer.